Sorafenib combined with TACE in advanced primary hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 60, Issue 121, 2013, Pages 305-310

  Cui, Han Zhi ^a   Dai, Guang Hai ^b   Shi, Yan ^b   Chen, Li ^b  

^a 309TH HOSPITAL OF PLA   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Primary hepatocellular carcinoma; Sorafenib; TACE

Indexed keywords

SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; APPETITE; ARTICLE; CANCER CONTROL; CANCER REGRESSION; CHEMOEMBOLIZATION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HAND FEET SKIN REACTION; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84877702569     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge12552     Document Type: Article

References (17)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108. (Pubitemid 40372904)
2. TF Green, F Korangy, MP Manns, et al.: Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer 2009; 100:19-23.
3. Llovet JM, Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48:20-37.
4. Llovet J, Ricci S, Mazzafemo V, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4):378-390.
5. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guide lines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92(10):205-216. (Pubitemid 30099779)
6. Llovet JM, Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48(4):1312-1327.
7. Masatoshi K, Kazuho I, Nobuyuki C, et al.: Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; 47:2117-2127.
8. Sung WS: The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol 2009; 10(5):425-434.
9. Fernádez M, Semela D, Bruix J, et al.: Angiogenesis in liver disease. J Hepatol 2009; 50:604-620.
10. Wang B, Xu H, Gao ZQ, et al.: Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 2008; 49(5):523-529.
11. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000; 407(6801):249-257.
12. Marelli L, Stigliano R, Triantos C, et al.: Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30:6-25. (Pubitemid 44900485)
13. Shi M, Chen JA, Lin XJ, et al.: Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. World J Gastroenterol 2010; 16(2):264-269.
14. Li Y, Huang JW, Lu LG, et al.:Clinical analysis of the treatment: transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi 2010; 90(31):2187-2192.
15. So BJ, Bekaii-Saab T, Bloomston MA, et al.: Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report. J H ematol Oncol 2008; 1:18.
16. Pawlik TM, Reyes DK, Cosgrove D, et al.: Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 2011; 29(30):3960-3967.
17. Abou-Alfa GK: TACE and Sorafenib: A good marriage? J Clin Oncol 2011; 29(30):3949-3952.